CXCR4 and hepatocellular carcinoma: Indeed, formulation of sorafenib in CXCR4-targeted lipid-coated poly (lactic-coglycolic acid) (PLGA) NPs modified with AMD3100 efficiently delivers sorafenib into HCC and human umbilical vein endothelial cells to achieve cytotoxicity and anti-angiogenic effect in vitro and in vivo.